Jack Anders sold $3.4M of RVMD
Chief Financial Officer at Revolution Medicines, Inc.. 20,000 shares at an average of $168.33, traded Jun 24, 2026, filed Jun 26, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.4M at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-26-000296, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $18.56 | $371k | 143,269 | Jun 26, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -4,553 | $167.35 | $762k | 138,716 | Jun 26, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -9,496 | $168.20 | $1.6M | 129,220 | Jun 26, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -5,651 | $169.24 | $956k | 123,569 | Jun 26, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -300 | $170.32 | $51k | 123,269 | Jun 26, 2026 |
| Jun 24, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +20,000 | $0.00 | $0 | 20,600 | Jun 26, 2026 |
Related signals
Other insiders at Revolution Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Revolution Medicines, Inc. | Alan B. Sandler Chief Development Officer | $1.3M 6,309 shares | -11% | |
| 21Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $159k 765 shares | -1% | |
| 16Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $743k 3,708 shares | -9% | |
| 40Moderate | Revolution Medicines, Inc. | Elizabeth M Anderson director | $2.0M 10,143 shares | -70% | |
| 25Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $347k 1,764 shares | -4% | |
| 39Weak | Revolution Medicines, Inc. | Jack Anders Chief Financial Officer | $808k 4,053 shares | -3% | |
| 30Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $671k 3,366 shares | -6% | |
| 35Weak | Revolution Medicines, Inc. | Mark A Goldsmith See Remarks | $2.8M 13,988 shares | -5% | |
| 40Moderate | Revolution Medicines, Inc. | Margaret A Horn Chief Operating Officer | $990k 4,967 shares | -3% | |
| 35Weak | Revolution Medicines, Inc. | Stephen Michael Kelsey See Remarks | $1.1M 5,569 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.